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Background: We recently described a multilocus sequence typing scheme for Achromobacter that identiﬁed several novel species in this genus.
Methods:We assessed the ability of nrdA sequence analysis to differentiate Achromobacter species, including the seven previously named species
and 14 recently described genogroups. Conﬁrmation of distinctness between groups was conﬁrmed using the k parameter. Using this single locus
sequence to differentiate species, we analyzed Achromobacter isolates obtained from 341 CF patients in the U.S.
Results:We found that Achromobacter xylosoxidans accounts for 42% of Achromobacter infections, while Achromobacter ruhlandii accounted for
23.5% of infections. Isolates from 17% of patients were members of the novel genogroup 14. The remaining 17.5% of strains belonged to 11 other
species/genogroups.
Conclusion: The use of nrdA sequence analysis allows differentiation of the several Achromobacter species that can infect persons with CF.
Achromobacter species other than A. xylosoxidans account for the majority of Achromobacter infection in CF patients in the U.S.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Achromobacter; Infection; Taxonomy; Clinical microbiology1. Introduction
Achromobacter xylosoxidans is well recognized as an
opportunistic pathogen infecting persons with cystic fibrosis
(CF) [1]. The remaining six currently named Achromobacter
species, including Achromobacter ruhlandii, Achromobacter
piechaudii, Achromobacter denitrificans, Achromobacter spanius,
Achromobacter insolitus and Achromobacter marplatensis, are
inhabitants of soil and have been much less frequently associated
with human infection [2–5].
We recently developed a multi-locus sequence typing
(MLST) scheme that, in addition to clearly distinguishing
these seven Achromobacter species, identified an additional
14 novel genogroups, each of which is genetically distinct
enough to represent a novel species [6]. In that study, we⁎ Corresponding author at: Department of Pediatrics and Communicable Diseases,
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scheme, nrdA, appeared to be able to distinguish these 21
taxa. We further noted that approximately half of the
Achromobacter isolates included in the study, the great
majority of which had been recovered from CF and non-CF
clinical sources, were species other than A. xylosoxidans. In
the current study, we sought to validate the use of nrdA
sequence as a means to differentiate Achromobacter species
and to determine the distribution of these species among
Achromobacter-infected CF patients in the U.S.
2. Methods
2.1. nrdA analysis
Amplification and DNA sequencing of nrdA was performed
as described [6]. Sequences were trimmed to 765 bp and aligned
using MegAlign (DNASTAR, Madison, WI, USA) with Clustal
W to generate a dendrogram with 1000 bootstrap replications
using the default parameters in MegAlign. All nrdA sequencesby Elsevier B.V. All rights reserved.
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achromobacter [7]. For validation of distinctness of sequence
similarity clusters, the k parameter was calculated [8]. This
metric represents the distinctness of populations, expressed
as a ratio (k) of the expected divergence between populations
to the expected divergence within a population. The expected
divergence within populations is determined largely by the
diversity-purging effect of periodic selection, which is in turn
determined by the rate of recombination within populations
and the intensity of the periodic selection. The k parameter is
calculated as the ratio of the mean inter-group sequence
divergence to the mean intra-group sequence divergence. A k
parameter greater than 2 indicates that a group is distinct from
its closest neighbor.
2.2. Species distribution
A review of isolates referred to the Burkholderia cepacia
Research Laboratory and Repository (University of Michigan,
USA) identified 341 CF patients from whom Achromobacter had
been recovered from respiratory specimens. Isolates had been
referred from 86 CF treatment centers in the U.S. between 1998
and 2012. A single isolate from each patient was included in this
study. In cases where multiple Achromobacter isolates were
available from the same patient, the first isolate received was
used. Fifty-five of the 341 isolates had previously been analyzed
by the recently described MLST scheme [6]. For the remaining
286 isolates, only nrdA was amplified and sequenced.
3. Results
As expected, among the set of 55 isolates for which both nrdA
sequence and MLST analyses had been performed, fewer nrdA
alleles (n=39) were detected than were MLST sequence types
(n=55).
A dendrogram based on the full complement of concatenat-
ed MLST loci (2249 bp) from 47 Achromobacter strains
(representing strains from each species, genogroup, or subgroup)
was compared to the dendrogram based on nrdA sequence alone
(765 bp) for these same 47 strains (Supplemental Fig. 1). The
separation of strains into distinct groups in the nrdA tree matched
the separation of strains into the 21 species and genogroups found
in the concatenated MLST tree. Bootstrap values supported this
clustering in the nrdA sequence tree. A dendrogram with
bootstrap support of clusters showing all unique nrdA sequence
types identified among isolates from the 341 CF patients is
provided in the Supplemental Information.
Similar to the results we obtained previously by using
concatenated MLST sequences [6], k parameter calculations
indicated that nrdA sequence alone separatedmost of the 21 species
and genogroups into genetically distinct groups; k parameters
ranged from 2.5 to 40.9 for these groups (Supplementary data
Table 1). The exceptions were with genogroups 4, 5a, and
A. ruhlandii, which were not found to be distinct from their closest
neighbors (k=1.3, 1.6 and 1.9, respectively). It should be noted,
however, that both genogroup 4 and A. ruhlandiiwere shown to be
distinct groups based on the k parameters calculated using datafrom the full MLST scheme as we described previously [6]. In that
analysis, only genogroup 5 could not be shown to be distinct;
but, this may be a function of the next closest group (genogroup
7) containing only two strains. It is not clear whether or not k
parameters would support distinct groups with the addition of
more strains. Nevertheless, all three groups segregate into
distinct clusters in the three trees presented in the Supplemental
Information.
Analysis of nrdA sequences demonstrated thatA. xylosoxidans
accounted for only 143 (42%) of Achromobacter infection in our
cohort of 341 CF patients (Fig. 1). A. ruhlandii accounted for
23.5% of Achromobacter infection, while 17% of the strains
were genogroup 14. We identified no individuals infected with
A. marplatensis, A. piechaudii, or genogroups 1, 9, 10, 11 or 12.
4. Discussion
Our previous work developing a genus-level MLST scheme for
Achromobacter, based on loci from seven housekeeping genes
demonstrated several novel genogroups in this genus [6].
Phylogenetic analyses provided compelling evidence that these
genogroups represented novel Achromobacter species; this is
supported by on-going comprehensive taxonomic studies, includ-
ing DNA–DNA hybridizations (manuscripts in preparation). In a
similar recent study, Ridderberg et al. [9] employed multilocus
sequence analysis (MLSA) based on five housekeeping genes
(with only one, rpoB, in commonwith ourMLST scheme) to study
a collection of 77 Achromobacter strains, including type strains of
the seven recognized species, as well as environmental and clinical
strains originating in Europe, Asia, and South America. They too
were able to differentiate the current Achromobacter species and
identified four novel genogroups.
In our analyses, and as reported by Ridderberg et al. [9],
sequence analysis of the bacterial 16S rRNA gene was inadequate
in differentiating novel and established Achromobacter species.
However, in developing our MLST scheme, we noted that another
locus, nrdA, appeared capable of clustering strains into species-
level groups. This was supported by the comparison of a
dendrogram based on a 765 bp internal nrdA fragment with a
tree composed of the 2249 bp concatenated MLST sequences.
Although, as expected, the topology of the trees differed, since
nrdA sequence alone is more limited in providing phylogenetic
inferences relative to the full MLST sequence data, both trees
clustered strains into groups representing all 21 Achromobacter
species and genogroups. Phylogenetic analyses, including k
parameter calculation and bootstrapping analyses, supported the
utility of the nrdA locus in differentiating most groups. Increasing
the numbers of strains analyzed may increase the k parameters for
the three groups with low levels of distinctness based on this single
locus.
Having established that nrdA sequence analysis provides for
species-level separation of established and novel Achromobacter
species, we used this locus to determine the identity of isolates
recovered from all individuals from whom we had previously
confirmed the recovery of Achromobacter. We limited this set to
individuals who were registered in the Cystic Fibrosis Founda-
tion Patient Registry [10], thereby confirming that each, in fact,
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Fig. 1. Distribution of Achromobacter species/genogroups isolated from 341 CF patients. Achromobacter species/genogroups are listed top to bottom in order from
most to least abundant. The numbers in each wedge indicate the number of patients infected with the species/genogroup.
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identified as A. xylosoxidans by commercial test systems in the
referring laboratories. We found, however, that this species
accounted for the minority (42%) of Achromobacter infection in
U.S. CF patients. A. xylosoxidans accounted for 64% of infection
in the 56 CF patients studied by Ridderberg et al. [9].
A. ruhlandii was found in nearly one-quarter of our patients.
It is clear that commercial test systems do not identify this
species, which was formally described in 1998 [11]. Of interest,
Ridderberg et al. [9] found that the Danish epidemic strain
(DES), an exceptionally resistant Achromobacter clone causing
infection in Copenhagen [12] and Aarhus [13], is identified as
A. ruhlandii based on their MLSA scheme.
We found that 17% of patients were infected by a novel
Achromobacter genogroup (genogroup 14), while Ridderberg
noted 18% of patients were infected with a novel species (their
MLSA cluster III). Our preliminary analysis suggests that these
two groups do not represent the same species. We further found
that only six of the 21 Achromobacter species/genogroups
(A. xylosoxidans, A. ruhlandii, A. insolitus, and genogroups 14,
2a, 2b, 5a and 5b) account for 94% of Achromobacter infection
in CF patients in the U.S. Of note, we identified no patients
infected with A. marplatensis, a recently described species that is
phylogenetically very closely related to A. xylosoxidans [4,6].
This observation suggests that despite their very close genetic
relatedness these two species differ in their capacity for human
infection (and/or their biogeography), suggesting that a compar-
ative study of these two taxa may prove useful in elucidating
factors involved in A. xylosoxidans pathogenicity.
Most studies addressing the impact of Achromobacter
infection on clinical outcomes in CF have concluded that
infection does not appreciably seem to affect clinical course
[14–16]. Nevertheless, it appears that some specific clones are
associated with increased rates of pulmonary decline [12,17,18].
The recognition that several distinct Achromobacter species are
responsible for infection in CF patients now provides an
opportunity to determine whether certain species are more likely
associated with poor outcome than others.Acknowledgments
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